Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2002; 39:1269-1274
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al-Hesayen, A.
Right arrow Articles by Parker, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Hesayen, A.
Right arrow Articles by Parker, J. D.

The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure

Abdul Al-Hesayen, MD*, Eduardo R. Azevedo, MD*, Gary E. Newton, MD* and John D. Parker, MD, FACC*,*

* Division of Cardiology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Canada



View larger version (19K):

[in a new window]
 
Figure 1 Cardiac norepinephrine spillover rate (CANESP) with dobutamine in the congestive heart failure (CHF) group versus the normal left ventricular (LV) function group. Solid triangle = normal LV on no beta-blocker; open triangle = normal LV on beta-blocker; open circle = CHF on no beta-blocker; solid circle = CHF on beta-blocker. C = control; Dob = Dobutamine. *p < 0.05 vs. control; {dagger}p < 0.05 response in CHF group versus response in normal LV group.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement